BRPI0519317A2 - mÉtodo para marcar um vetor, composto, composiÇço radiofarmacÊutica, uso de um composto, e, mÉtodos para gerar uma imagem de um corpo humano ou animal e para monitorar o efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condiÇço associada com cÂncer - Google Patents
mÉtodo para marcar um vetor, composto, composiÇço radiofarmacÊutica, uso de um composto, e, mÉtodos para gerar uma imagem de um corpo humano ou animal e para monitorar o efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condiÇço associada com cÂncerInfo
- Publication number
- BRPI0519317A2 BRPI0519317A2 BRPI0519317-6A BRPI0519317A BRPI0519317A2 BR PI0519317 A2 BRPI0519317 A2 BR PI0519317A2 BR PI0519317 A BRPI0519317 A BR PI0519317A BR PI0519317 A2 BRPI0519317 A2 BR PI0519317A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- human
- animal body
- methods
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
MÉTODO PARA MARCAR UM VETOR, COMPOSTO, COMPOSIÇçO RADIOFARMACÊUTICA, USO DE UM COMPOSTO, E, MÉTODOS PARA GERAR UMA IMAGEM DE UM CORPO HUMANO OU ANIMAL E PARA MONITORAR O EFEITO DO TRATAMENTO DE UM CORPO HUMANO OU ANIMAL COM UMA DROGA PARA COMBATER UMA CONDIÇçO ASSOCIADA COM CÂNCER. A invenção diz respeito a agentes de radiodiagnóstico e radioterapêuticos, incluindo vetores biologicamente ativos marcados com radionuclídeos. Ainda diz respeito aos métodos e reagentes que marcam um vetor tal como um peptídeo compreendendo a reação de um composto de fórmula (I) com um composto de fórmula (II) ou, um composto de fórmula (III) com um composto de fórmula (IV) na presença de um catalisador de Cu (1). Os conjugados marcados resultantes são úteis como agentes de diagnóstico, por exemplo, como radiofarmacéuticos mais especificamente para uso na Tomografia por Emissão de Pósitron (PET) ou Tomografia Computadorizada por Emissão de Mono-fótons (SPECT) ou para radioterapia.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0428012.9A GB0428012D0 (en) | 2004-12-22 | 2004-12-22 | Radiolabelling methods |
PCT/GB2005/004729 WO2006067376A2 (en) | 2004-12-22 | 2005-12-09 | Radiolabelled conjugates of rgd-containing peptides and methods for their preparation via click-chemistry |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0519317A2 true BRPI0519317A2 (pt) | 2009-01-13 |
Family
ID=34112991
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0519317-6A BRPI0519317A2 (pt) | 2004-12-22 | 2005-12-09 | mÉtodo para marcar um vetor, composto, composiÇço radiofarmacÊutica, uso de um composto, e, mÉtodos para gerar uma imagem de um corpo humano ou animal e para monitorar o efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condiÇço associada com cÂncer |
Country Status (13)
Country | Link |
---|---|
US (2) | US7972588B2 (pt) |
EP (4) | EP2275145A1 (pt) |
JP (2) | JP5743372B2 (pt) |
KR (1) | KR101314460B1 (pt) |
CN (2) | CN105012972A (pt) |
AU (1) | AU2005317903C1 (pt) |
BR (1) | BRPI0519317A2 (pt) |
CA (2) | CA2589136C (pt) |
GB (1) | GB0428012D0 (pt) |
MX (1) | MX2007007560A (pt) |
NO (1) | NO341638B1 (pt) |
RU (1) | RU2419627C2 (pt) |
WO (1) | WO2006067376A2 (pt) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0428012D0 (en) * | 2004-12-22 | 2005-01-26 | Hammersmith Imanet Ltd | Radiolabelling methods |
US8071718B2 (en) | 2004-12-22 | 2011-12-06 | General Electric Company | Selective radiolabeling of biomolecules |
WO2007148089A2 (en) * | 2006-06-21 | 2007-12-27 | Hammersmith Imanet Limited | Radiolabelling methods |
EP2029616A1 (en) * | 2006-06-21 | 2009-03-04 | Hammersmith Imanet Limited | Chemical methods and apparatus |
US20100233082A1 (en) * | 2006-08-28 | 2010-09-16 | Bengt Langstrom | 68GA-Labeled Peptide-Based Radiopharmaceuticals |
WO2008025886A1 (en) * | 2006-09-01 | 2008-03-06 | Wallac Oy | Metal chelates and chelating agents containing triazolyl subunits |
JP2010526999A (ja) * | 2007-05-10 | 2010-08-05 | トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク | Petを用いた疾患の診断法及びその治療の評価法 |
CN101903047B (zh) * | 2007-12-20 | 2015-10-21 | 通用电气公司 | 生物分子的选择性放射性标记 |
EP2147684A1 (en) * | 2008-07-22 | 2010-01-27 | Bracco Imaging S.p.A | Diagnostic Agents Selective Against Metalloproteases |
GB0815831D0 (en) * | 2008-09-01 | 2008-10-08 | Imp Innovations Ltd | Compounds |
AU2009289062B2 (en) | 2008-09-05 | 2015-01-22 | Hammersmith Imanet Limited | Isatin derivatives for use as in vivo imaging agents |
EP2346870B1 (en) * | 2008-10-10 | 2015-08-05 | Merck & Cie | 18f-labelled folates as pet radiotracers |
US20120165650A1 (en) | 2010-12-22 | 2012-06-28 | General Electric Company | Her2 binders |
EP2210882A1 (en) * | 2009-01-16 | 2010-07-28 | Commissariat à l'Énergie Atomique et aux Énergies Alternatives | Synthesis of new protected azahistidine, their processes and their use in synthesises |
EP2400992B1 (en) * | 2009-02-27 | 2015-07-22 | Genentech, Inc. | Methods and compositions for protein labelling |
US8722014B2 (en) * | 2009-05-01 | 2014-05-13 | Washington University | 1 H-[1, 2, 3] triazole substituted amino acids and uses thereof |
GB0914543D0 (en) | 2009-08-20 | 2009-09-30 | Ge Healthcare Ltd | Radioiodination method |
EP2498826A1 (en) * | 2009-11-11 | 2012-09-19 | NeuroSearch AS | Labelled pyrrolyl-oxadiazolyl-diazabicyclononane derivatives and their use in diagnostic methods |
GB0921573D0 (en) * | 2009-12-10 | 2010-01-27 | Ge Healthcare Ltd | Iodine radiolabelling method |
GB0922304D0 (en) | 2009-12-22 | 2010-02-03 | Ge Healthcare Ltd | Radioiodinated compounds |
EP2515650A4 (en) * | 2009-12-23 | 2013-05-29 | Univ Nebraska | TARGETED RADIOMARTICATED COMPOUNDS AND THEIR USE FOR THE TREATMENT AND DIAGNOSIS OF CANCER |
US9517279B2 (en) * | 2010-04-14 | 2016-12-13 | The Mclean Hospital Corporation | 2-alkoxy-11-hydroxyaporphine derivatives and uses thereof |
CA2801064A1 (en) * | 2010-06-01 | 2011-12-08 | Advanced Proteome Therapeutics Inc. | Crosslinking of proteins and other entities via conjugates of alpha-haloacetophenones, benzyl halides, quinones, and their derivatives |
CN103221398B (zh) * | 2010-07-23 | 2016-03-23 | 特拉华大学 | 用于快速构建放射性核素标记探针的四嗪-反式环辛烯连接反应 |
GB201014023D0 (en) * | 2010-08-20 | 2010-10-06 | Ucl Business Plc | Process for producing bioconjugates and products thereof |
US9649394B2 (en) | 2010-11-22 | 2017-05-16 | The General Hospital Corporation | Compositions and methods for in vivo imaging |
GB201019824D0 (en) | 2010-11-23 | 2011-01-05 | Ge Healthcare Ltd | Radioiodination method |
GB201021369D0 (en) | 2010-12-16 | 2011-01-26 | Ge Healthcare Ltd | Radioiodinated fatty acids |
GB201021517D0 (en) | 2010-12-20 | 2011-02-02 | Ge Healthcare Ltd | Radioiodinated guanidines |
EP2661284A1 (en) | 2010-12-22 | 2013-11-13 | GE Healthcare UK Limited | Her2 binding peptides labelled with a 18f - containing organosilicon compound |
CA3159948A1 (en) | 2010-12-22 | 2012-07-19 | General Electric Company | Radiolabled her2 binding peptides |
WO2012118909A1 (en) | 2011-03-01 | 2012-09-07 | Ge Healthcare Limited | Radiolabelled octreotate analogues as pet tracers |
US20120251448A1 (en) * | 2011-03-03 | 2012-10-04 | Hefti Franz F | Compounds for Use in the Detection of Neurodegenerative Diseases |
US9023318B2 (en) * | 2011-06-08 | 2015-05-05 | Siemens Medical Solutions Usa, Inc. | Compounds with matrix-metalloproteinase inhibitory activity and imaging agents thereof |
WO2013048832A1 (en) | 2011-09-29 | 2013-04-04 | Ge Healthcare Limited | 18 f - labelled 6 - ( 2 - fluoroethoxy) - 2 - naphthaldehyde for detecting cancer stem cells |
WO2013048811A1 (en) | 2011-09-30 | 2013-04-04 | Ge Healthcare Limited | Imaging and radiotherapy methods for tumour stem cells |
WO2013082508A1 (en) * | 2011-12-02 | 2013-06-06 | The Regents Of The University Of Michigan | Compositions and methods for the treatment and analysis of neurological disorders |
GB201121911D0 (en) | 2011-12-20 | 2012-02-01 | Ge Healthcare Ltd | Radiofluorination method |
EP2809356A1 (en) * | 2012-02-03 | 2014-12-10 | Aarhus Universitet | Radiolabeled bile acids and bile acid derivatives |
EP2657213A1 (en) * | 2012-04-24 | 2013-10-30 | Institut National de la Santé et de la Recherche Medicale | Labelled quinoxaline derivatives as multimodal radiopharmaceuticals and their precursors |
US20140065070A1 (en) * | 2012-08-28 | 2014-03-06 | Mcmaster University | Methods of preparing triazole-containing radioiodinated compounds |
WO2014065413A1 (ja) * | 2012-10-26 | 2014-05-01 | 日本たばこ産業株式会社 | トリアゾール・イソオキサゾール化合物およびその医薬用途 |
US20150023877A1 (en) * | 2013-07-18 | 2015-01-22 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of parkinsons disease diagnosis and monitoring treatment |
ES2700348T3 (es) * | 2014-01-05 | 2019-02-15 | Univ Washington | Trazadores radioetiquetados para poli (ADP-ribosa) polimerasa-1 (PARP-1), métodos y usos para estos |
US20160022846A1 (en) * | 2014-07-22 | 2016-01-28 | Ge Healthcare Limited | Iodine radiolabelling method |
MY189024A (en) * | 2015-06-19 | 2022-01-20 | Eisai R&D Man Co Ltd | Cys80 conjugated immunoglobulins |
WO2017023999A1 (en) * | 2015-08-03 | 2017-02-09 | Emory University | Methylsulfonamide derivatives and uses related thereto |
EP3826673A4 (en) * | 2018-07-26 | 2022-03-09 | Tayu Huaxia Biotech Medical Group Co., Ltd. | IMAGING COMPOSITIONS AND METHODS |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4913891A (en) * | 1986-04-17 | 1990-04-03 | The United States Of America As Represented By The United States Department Of Energy | Positron emitter labeled enzyme inhibitors |
AU4589701A (en) | 2000-03-24 | 2001-10-08 | Cocensys Inc | Aryl substituted pyrazoles, triazoles and tetrazoles, and the use thereof |
US6350360B1 (en) | 2000-04-07 | 2002-02-26 | Sandia Coroporation | Method of fabricating a 3-dimensional tool master |
EP1272507B1 (en) * | 2000-04-12 | 2005-06-29 | Amersham Health AS | Integrin binding peptide derivatives |
GB0115927D0 (en) | 2001-06-29 | 2001-08-22 | Nycomed Amersham Plc | Solid-phase nucleophilic fluorination |
NZ530156A (en) * | 2001-07-10 | 2007-04-27 | Ge Healthcare As | Peptide-based compounds for targeting integrin receptors for use as diagnostic imaging agents |
KR101138643B1 (ko) | 2002-05-30 | 2012-04-26 | 더 스크립스 리서치 인스티튜트 | 구리 촉매 작용하에서의 아지드와 아세틸렌과의 리게이션 |
WO2004055160A2 (en) | 2002-12-13 | 2004-07-01 | The Trustees Of Columbia University In The City Of New York | Biomolecular coupling methods using 1,3-dipolar cycloaddition chemistry |
JP5642916B2 (ja) | 2003-04-17 | 2014-12-17 | ザ スクリプス リサーチ インスティテュート | 真核遺伝コードの拡張 |
US7993872B2 (en) | 2003-06-18 | 2011-08-09 | The Scripps Research Institute | Unnatural reactive amino acid genetic code additions |
NO20033115D0 (no) | 2003-07-08 | 2003-07-08 | Amersham Health As | Peptid-baserte forbindelser |
WO2006038185A2 (en) * | 2004-10-07 | 2006-04-13 | Koninklijke Philips Electronics N.V. | Use of the staudinger ligation in imaging and therapy end kits for imaging and therapy |
GB0428012D0 (en) * | 2004-12-22 | 2005-01-26 | Hammersmith Imanet Ltd | Radiolabelling methods |
-
2004
- 2004-12-22 GB GBGB0428012.9A patent/GB0428012D0/en not_active Ceased
-
2005
- 2005-12-09 CA CA2589136A patent/CA2589136C/en not_active Expired - Fee Related
- 2005-12-09 AU AU2005317903A patent/AU2005317903C1/en not_active Ceased
- 2005-12-09 MX MX2007007560A patent/MX2007007560A/es active IP Right Grant
- 2005-12-09 BR BRPI0519317-6A patent/BRPI0519317A2/pt not_active Application Discontinuation
- 2005-12-09 WO PCT/GB2005/004729 patent/WO2006067376A2/en active Application Filing
- 2005-12-09 CN CN201510494983.3A patent/CN105012972A/zh active Pending
- 2005-12-09 EP EP20100179449 patent/EP2275145A1/en not_active Withdrawn
- 2005-12-09 US US11/721,694 patent/US7972588B2/en active Active
- 2005-12-09 EP EP10179446.9A patent/EP2266629B1/en active Active
- 2005-12-09 RU RU2007122804/04A patent/RU2419627C2/ru not_active IP Right Cessation
- 2005-12-09 JP JP2007547612A patent/JP5743372B2/ja active Active
- 2005-12-09 EP EP20100179459 patent/EP2258403A1/en not_active Withdrawn
- 2005-12-09 KR KR1020077014048A patent/KR101314460B1/ko not_active IP Right Cessation
- 2005-12-09 CA CA2817636A patent/CA2817636A1/en not_active Abandoned
- 2005-12-09 EP EP05818037A patent/EP1830890A2/en not_active Withdrawn
- 2005-12-09 CN CNA2005800441130A patent/CN101084020A/zh active Pending
-
2007
- 2007-06-20 NO NO20073157A patent/NO341638B1/no not_active IP Right Cessation
-
2011
- 2011-06-13 US US13/158,555 patent/US8679455B2/en active Active
-
2012
- 2012-07-30 JP JP2012167865A patent/JP2012254998A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP2266629B1 (en) | 2015-12-09 |
AU2005317903C1 (en) | 2012-05-10 |
CA2589136A1 (en) | 2006-06-29 |
CA2817636A1 (en) | 2006-06-29 |
AU2005317903B8 (en) | 2012-01-19 |
JP5743372B2 (ja) | 2015-07-01 |
CA2589136C (en) | 2015-10-06 |
US8679455B2 (en) | 2014-03-25 |
WO2006067376A2 (en) | 2006-06-29 |
US7972588B2 (en) | 2011-07-05 |
RU2007122804A (ru) | 2009-01-27 |
AU2005317903B2 (en) | 2011-12-01 |
CN105012972A (zh) | 2015-11-04 |
RU2419627C2 (ru) | 2011-05-27 |
KR20070091626A (ko) | 2007-09-11 |
EP2266629A1 (en) | 2010-12-29 |
KR101314460B1 (ko) | 2013-10-10 |
GB0428012D0 (en) | 2005-01-26 |
WO2006067376A3 (en) | 2007-07-26 |
US20090311177A1 (en) | 2009-12-17 |
JP2012254998A (ja) | 2012-12-27 |
EP1830890A2 (en) | 2007-09-12 |
NO341638B1 (no) | 2017-12-18 |
US20110236311A1 (en) | 2011-09-29 |
CN101084020A (zh) | 2007-12-05 |
AU2005317903A1 (en) | 2006-06-29 |
EP2275145A1 (en) | 2011-01-19 |
JP2008528445A (ja) | 2008-07-31 |
NO20073157L (no) | 2007-06-20 |
MX2007007560A (es) | 2007-11-21 |
EP2258403A1 (en) | 2010-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0519317A2 (pt) | mÉtodo para marcar um vetor, composto, composiÇço radiofarmacÊutica, uso de um composto, e, mÉtodos para gerar uma imagem de um corpo humano ou animal e para monitorar o efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condiÇço associada com cÂncer | |
Müller et al. | Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer | |
WO2007148089A3 (en) | Radiolabelling methods | |
Jamous et al. | Synthesis of peptide radiopharmaceuticals for the therapy and diagnosis of tumor diseases | |
bin Othman et al. | Re-assessing gallium-67 as a therapeutic radionuclide | |
Naji et al. | 68 Ga-labelled peptides in the management of neuroectodermal tumours | |
NZ606466A (en) | Peptide radiotracer compositions | |
WO2008033561A3 (en) | Click chemistry-derived cyclopeptide derivatives as imaging agents for integrins | |
BRPI0518636A2 (pt) | kits nço-radioativo liofilizado e de multi-doses, processo para a preparaÇço de méltiplas doses de paciente unitÁrias do radiofarmacÊutico tetrofosmina-99mtc, composiÇço radiofarmacÊutica estabilizada, e, dose de paciente unitÁria do radiofarmacÊutico tetrofosmina-99mtc | |
ATE411819T1 (de) | Konjugate für medizinische abbildungen umfassend träger, targeting-anteile und kontrastmittel | |
CN107438615A (zh) | 用于制备放射性核素络合物的方法和试剂盒 | |
Boschi et al. | 188Re (V) nitrido radiopharmaceuticals for radionuclide therapy | |
WO2009134405A3 (en) | Substrate based pet imaging agents | |
Maschauer et al. | In vivo monitoring of the antiangiogenic effect of neurotensin receptor-mediated radiotherapy by small-animal positron emission tomography: a pilot study | |
WO2009018175A3 (en) | Cyclic azapeptides as integrin markers | |
WO2009134382A3 (en) | Cyclopeptides containing rgd mimetics as imaging markers for integrins | |
Kanellopoulos et al. | Key-protease inhibition regimens promote tumor targeting of neurotensin radioligands | |
Prior et al. | Radiopharmaceuticals in the elderly cancer patient: Practical considerations, with a focus on prostate cancer therapy: A position paper from the International Society of Geriatric Oncology Task Force | |
Miao et al. | Therapeutic efficacy of a 177Lu-labeled DOTA conjugated α-melanocyte-stimulating hormone peptide in a murine melanoma-bearing mouse model | |
Tehrani et al. | Evaluation of 99m Tc-MccJ25 peptide analog in mice bearing B16F10 melanoma tumor as a diagnostic radiotracer | |
Ramli et al. | Preclinical study of 177Lu-DOTA-trastuzumab: A potential radiopharmaceutical for therapy of breast cancer positive HER-2 | |
Tang et al. | Indium-111 labeled bleomycin for targeting diagnosis and therapy of liver tumor: optimized preparation, biodistribution and SPECT imaging with xenograft models | |
Eryilmaz et al. | Detailed chemistry studies of 225Actinium labeled radiopharmaceuticals | |
CA2914496A1 (en) | Treatment of immune, inflammatory and degenerative arthritides with tin-117m | |
Szücs et al. | Investigation of the effect on the albumin binding moiety for the pharmacokinetic properties of 68ga-, 205/206bi-, and 177Lu-Labeled NAPamide-Based radiopharmaceuticals |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI. |
|
B07A | Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O C/C 11, 8O C/C 13 E 25 DA LPI. |
|
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |